BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Soverini, Simona; Hochhaus, Andreas; E. Nicolini, Franck; Gruber, Franz; Lange, Thoralf; Saglio, Giuseppe; Pane, Fabrizio; C. Müller, Martin; Ernst, Thomas; Rosti, Gianantonio; Porkka, Kimmo; Baccarani, Michele; C.P. Cross, Nicholas; Martinelli, Giovanni

doi:10.1182/blood-2010-12-326405

Public

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Published in Blood • May 12, 2011

Authors:

Simona Soverini

Andreas Hochhaus

Franck E. Nicolini

Abstract

Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations aimed to rationalize the use of BCR-ABL mutation testing in chronic myeloid leukemia have been compiled by a panel of experts appo...

Subject

Medicine

Imatinib

Myeloid leukemia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!